logo-loader
viewMotif Bio PLC

Motif Bio PLC chief looking to add “one or two partners during 2016”

It has been a busy few months for Motif Bio PLC (LON:MTFB), the company behind next-generation antibiotic, iclaprim, and chief executive Graham Lumsden speaks to Proactive.

The firm recently passed a major milestone when it dosed its first patient in one of two phase III clinical trials it is carrying out, and just this week announced the appointment of specialist adviser, The Fulford Group to assist with the commercialisation of the treatment.

Lumsden says the company is looking for “one or two partners during 2016” to help commercialise iclaprim globally, and that the Fulford Group, which “specialises in finding partners for companies like Motif,” will aid the firm to do this.

Quick facts: Motif Bio PLC

Price: 0.7945 GBX

AIM:MTFB
Market: AIM
Market Cap: £5.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Thunderbird Entertainment sees strong third quarter results...

Thunderbird Entertainment (CVE: TBRD-OTC: THBRF) CEO Jennifer Twiner McCarron joined Steve Darling from Proactive Vancouver to share news the company has released their 3rd quarter financial numbers which saw a 40 per cent increase from Q-3 of last year. Twiner-McCarron talks about what led...

2 days, 4 hours ago

2 min read